Nurix Therapeutics (NRIX) analyst forecast and price target
Analyst forecast
Consensus of 16 analyst ratings
Based on 12 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| RBC Capital | Maintained | Outperform | $36.00 from $33.00 | Aug 10, 2026 |
| Needham | Maintained | Buy | $34.00 | Aug 4, 2026 |
| Morgan Stanley | Maintained | Overweight | $38.00 from $36.00 | Jul 28, 2026 |
| UBS | Maintained | Buy | $31.00 from $23.00 | Jul 22, 2026 |
| Mizuho | Maintained | Outperform | $34.00 from $30.00 | Jul 13, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $34.00 from $32.00 | Jul 10, 2026 |
| Needham | Maintained | Buy | $34.00 | Jul 10, 2026 |
| BTIG | Maintained | Buy | $32.00 | Jul 10, 2026 |
| RBC Capital | Maintained | Outperform | $33.00 from $30.00 | Jul 10, 2026 |
| Stifel | Maintained | Buy | $40.00 from $34.00 | Jul 10, 2026 |
| Truist Securities | Maintained | Buy | $34.00 from $32.00 | Jul 10, 2026 |
| Baird | Maintained | Outperform | $33.00 from $26.00 | Jun 18, 2026 |
| Needham | Maintained | Buy | $34.00 | Jun 15, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $32.00 | Jun 10, 2026 |
| BTIG | Maintained | Buy | $32.00 from $30.00 | Jun 9, 2026 |
| Truist Securities | Maintained | Buy | $32.00 from $30.00 | Jun 9, 2026 |
| Needham | Maintained | Buy | $34.00 from $26.00 | Jun 8, 2026 |
| Jefferies | Maintained | Buy | $45.00 from $41.00 | Jun 8, 2026 |
| Wells Fargo | Maintained | Overweight | $25.00 from $28.00 | Jun 8, 2026 |
| BTIG | Maintained | Buy | $30.00 | May 18, 2026 |
Frequently asked questions
What is the price target for NRIX stock?
The average 12-month analyst price target for Nurix Therapeutics (NRIX) is $34.67, with a high estimate of $45.00 and a low of $25.00, across 12 analysts.
Is NRIX a buy, sell, or hold?
Analysts covering Nurix Therapeutics currently average a Buy rating: 15 buy, 1 hold and 0 sell, from 16 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for NRIX?
The average price target of $34.67 implies 34.47% upside from the last price of $25.78.
What is the latest analyst rating on NRIX?
On Aug 10, 2026, RBC Capital maintained Nurix Therapeutics at Outperform with a price target of $36.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.